• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心血管风险标志物不对称二甲基精氨酸(ADMA)与人类阳离子氨基酸转运蛋白 1(CAT1)的相互作用。

Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1).

机构信息

Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstraße 17, 91054 Erlangen, Germany.

出版信息

J Mol Cell Cardiol. 2012 Sep;53(3):392-400. doi: 10.1016/j.yjmcc.2012.06.002. Epub 2012 Jun 15.

DOI:10.1016/j.yjmcc.2012.06.002
PMID:22705145
Abstract

Elevated plasma concentrations of endogenously formed asymmetric (ADMA) and symmetric dimethyl-l-arginine (SDMA) are associated with adverse clinical outcomes. Our aim was to investigate the cellular uptake properties of ADMA by the human cationic amino acid transporter 1 (CAT1; SLC7A1). Human embryonic kidney cells (HEK293) stably overexpressing CAT1 (HEK-CAT1) and vector-transfected control cells (HEK-VC) were established to determine cellular uptake of labeled [(3)H]ADMA and [(3)H]l-arginine. Uptake of ADMA and l-arginine were significantly (p<0.001) higher in HEK-CAT1 than in HEK-VC at all investigated concentrations. Apparent V(max) values of cellular ADMA and l-arginine uptake by CAT1 were 26.9 ± 0.8 and 11.0 ± 0.2 nmol mg protein(-1) min(-1), respectively. K(m) values were 183 ± 21 μmoll(-1) (ADMA) and 519 ± 36 μmoll(-1) (l-arginine). Uptake of ADMA was inhibited by l-arginine and SDMA with IC(50) values (95% CI) of 227 (69-742) μmoll(-1) and 273 (191-390) μmoll(-1), respectively. ADMA and SDMA inhibited CAT1-mediated uptake of l-arginine with IC(50) values of 758 (460-1251) μmoll(-1) and 789 (481-1295) μmoll(-1), respectively. Efflux of ADMA was significantly increased in HEK-CAT1 cells as compared to HEK-VC (p<0.05). CAT1 mediates the cellular uptake of ADMA. In its physiological concentration range ADMA is unlikely to impair CAT1-mediated transport of l-arginine. Conversely, high (but still physiological) concentrations of l-arginine can inhibit CAT1-mediated cellular uptake of ADMA.

摘要

内源性形成的不对称(ADMA)和对称二甲基-l-精氨酸(SDMA)的血浆浓度升高与不良临床结局相关。我们的目的是研究人阳离子氨基酸转运蛋白 1(CAT1;SLC7A1)对 ADMA 的细胞摄取特性。建立了稳定过表达 CAT1 的人胚肾细胞(HEK293)(HEK-CAT1)和载体转染对照细胞(HEK-VC),以确定标记的 [(3)H]ADMA 和 [(3)H]l-精氨酸的细胞摄取。在所有研究的浓度下,ADMA 和 l-精氨酸在 HEK-CAT1 中的摄取均明显(p<0.001)高于 HEK-VC。CAT1 细胞 ADMA 和 l-精氨酸摄取的表观 V(max)值分别为 26.9 ± 0.8 和 11.0 ± 0.2 nmol mg 蛋白(-1) min(-1)。K(m)值分别为 183 ± 21 μmoll(-1)(ADMA)和 519 ± 36 μmoll(-1)(l-精氨酸)。ADMA 的摄取被 l-精氨酸和 SDMA 抑制,IC(50)值(95%CI)分别为 227(69-742)μmoll(-1)和 273(191-390)μmoll(-1)。ADMA 和 SDMA 抑制 CAT1 介导的 l-精氨酸摄取,IC(50)值分别为 758(460-1251)μmoll(-1)和 789(481-1295)μmoll(-1)。与 HEK-VC 相比,ADMA 在 HEK-CAT1 细胞中的外排明显增加(p<0.05)。CAT1 介导 ADMA 的细胞摄取。在其生理浓度范围内,ADMA 不太可能损害 CAT1 介导的 l-精氨酸转运。相反,高(但仍为生理)浓度的 l-精氨酸可以抑制 CAT1 介导的 ADMA 细胞摄取。

相似文献

1
Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1).心血管风险标志物不对称二甲基精氨酸(ADMA)与人类阳离子氨基酸转运蛋白 1(CAT1)的相互作用。
J Mol Cell Cardiol. 2012 Sep;53(3):392-400. doi: 10.1016/j.yjmcc.2012.06.002. Epub 2012 Jun 15.
2
The prognostic biomarker L-homoarginine is a substrate of the cationic amino acid transporters CAT1, CAT2A and CAT2B.预后生物标志物 L-高精氨酸是阳离子氨基酸转运体 CAT1、CAT2A 和 CAT2B 的底物。
Sci Rep. 2017 Jul 6;7(1):4767. doi: 10.1038/s41598-017-04965-2.
3
Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1).不对称二甲基精氨酸(ADMA)由阳离子氨基酸转运体 2(CAT2)、有机阳离子转运体 2(OCT2)和多药和毒素外排蛋白 1(MATE1)转运。
Amino Acids. 2013 Oct;45(4):989-1002. doi: 10.1007/s00726-013-1556-3. Epub 2013 Jul 18.
4
Screening of commonly prescribed drugs for effects on the CAT1-mediated transport of L-arginine and arginine derivatives.筛选常用药物对 CAT1 介导的 L-精氨酸及其衍生物转运的影响。
Amino Acids. 2022 Jul;54(7):1101-1108. doi: 10.1007/s00726-022-03156-2. Epub 2022 Apr 4.
5
The renal transport protein OATP4C1 mediates uptake of the uremic toxin asymmetric dimethylarginine (ADMA) and efflux of cardioprotective L-homoarginine.肾脏转运蛋白 OATP4C1 介导尿毒症毒素不对称二甲基精氨酸 (ADMA) 的摄取和心脏保护剂 L-同型精氨酸的外排。
PLoS One. 2019 Mar 13;14(3):e0213747. doi: 10.1371/journal.pone.0213747. eCollection 2019.
6
Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.缺血性急性肾损伤中对称二甲基精氨酸增加是导致肾脏精氨酸缺乏的原因之一。
Transl Res. 2013 Aug;162(2):67-76. doi: 10.1016/j.trsl.2013.04.005. Epub 2013 May 22.
7
The transporter and permeability interactions of asymmetric dimethylarginine (ADMA) and L-arginine with the human blood-brain barrier in vitro.不对称二甲基精氨酸(ADMA)和L-精氨酸与人血脑屏障在体外的转运体及通透性相互作用。
Brain Res. 2016 Oct 1;1648(Pt A):232-242. doi: 10.1016/j.brainres.2016.07.026. Epub 2016 Jul 16.
8
Real-time functional characterization of cationic amino acid transporters using a new FRET sensor.使用新型荧光共振能量转移传感器对阳离子氨基酸转运体进行实时功能表征。
Pflugers Arch. 2016 Apr;468(4):563-72. doi: 10.1007/s00424-015-1754-9. Epub 2015 Nov 11.
9
Plasma concentrations of arginine and asymmetric dimethylarginine do not reflect their intracellular concentrations in peripheral blood mononuclear cells.血浆中精氨酸和不对称二甲基精氨酸的浓度不能反映其在外周血单个核细胞中的浓度。
Metabolism. 2013 Oct;62(10):1455-61. doi: 10.1016/j.metabol.2013.05.017. Epub 2013 Jul 25.
10
Transport of L-Arginine Related Cardiovascular Risk Markers.L-精氨酸相关心血管风险标志物的转运
J Clin Med. 2020 Dec 8;9(12):3975. doi: 10.3390/jcm9123975.

引用本文的文献

1
Role of Transport Proteins for the Renal Handling of L-Arginine and Related Derivatives.转运蛋白在肾脏处理L-精氨酸及相关衍生物中的作用。
Int J Mol Sci. 2025 Aug 15;26(16):7899. doi: 10.3390/ijms26167899.
2
Enhancing therapeutic strategies and drug development for patients with kidney disease.改善肾病患者的治疗策略与药物研发。
Expert Opin Drug Saf. 2025 Jul 4:1-26. doi: 10.1080/14740338.2025.2525970.
3
Transport of the uremic toxin symmetric dimethylarginine (SDMA) by renal transport proteins.尿毒症毒素对称二甲基精氨酸(SDMA)通过肾脏转运蛋白的转运。
Amino Acids. 2025 Jun 25;57(1):34. doi: 10.1007/s00726-025-03466-1.
4
Saturation kinetics and specificity of transporters for L-arginine and asymmetric dimethylarginine (ADMA) at the blood-brain and blood-CSF barriers.血脑屏障和血脑脊液屏障处L-精氨酸和不对称二甲基精氨酸(ADMA)转运体的饱和动力学及特异性。
PLoS One. 2025 Jun 11;20(6):e0320034. doi: 10.1371/journal.pone.0320034. eCollection 2025.
5
Transient changes in L-arginine, asymmetric and symmetric dimethyl arginine in triathletes following Norseman Xtreme Triathlon.参加挪威人极限铁人三项赛后,铁人三项运动员体内L-精氨酸、不对称和对称二甲基精氨酸的短暂变化
Front Physiol. 2024 Oct 18;15:1451038. doi: 10.3389/fphys.2024.1451038. eCollection 2024.
6
L-Arginine and asymmetric dimethylarginine (ADMA) transport across the mouse blood-brain and blood-CSF barriers: Evidence of saturable transport at both interfaces and CNS to blood efflux.精氨酸和不对称二甲基精氨酸(ADMA)在小鼠血脑和血脑脊液屏障中的转运:在两个界面和中枢神经系统向血液流出均存在饱和转运的证据。
PLoS One. 2024 Oct 24;19(10):e0305318. doi: 10.1371/journal.pone.0305318. eCollection 2024.
7
SDMA as a marker and mediator in cerebrovascular disease.SDMA 在脑血管病中的标志物和介质作用。
Clin Sci (Lond). 2024 Oct 16;138(20):1305-1323. doi: 10.1042/CS20241021.
8
Integrative Analyses of Circulating Proteins and Metabolites Reveal Sex Differences in the Associations with Cardiac Function among DCM Patients.整合分析循环蛋白和代谢物揭示了 DCM 患者心脏功能与性别相关联的差异。
Int J Mol Sci. 2024 Jun 21;25(13):6827. doi: 10.3390/ijms25136827.
9
Arginine metabolomics in mood disorders.情绪障碍中的精氨酸代谢组学
Heliyon. 2024 Mar 14;10(6):e27292. doi: 10.1016/j.heliyon.2024.e27292. eCollection 2024 Mar 30.
10
Identification of transport systems involved in eflornithine delivery across the blood-brain barrier.参与依氟鸟氨酸通过血脑屏障转运的转运系统的鉴定。
Front Drug Deliv. 2023 May 23;3:1113493. doi: 10.3389/fddev.2023.1113493.